In a significant advancement for infant healthcare in India, Dr. Reddy’s Laboratories has officially launched Beyfortus® (nirsevimab), a novel preventive treatment for Respiratory Syncytial Virus (RSV) in infants. This launch follows the April 2025 announcement of their expanded partnership with Sanofi Healthcare India Private Limited that granted Dr. Reddy’s exclusive rights to promote and distribute the drug in India.
Addressing an Underreported Health Crisis
According to paediatric experts, RSV causes nearly two-thirds of respiratory infections in infants, yet cases are significantly underreported in India despite being a notifiable disease for decades. A representative of the Indian Academy of Pediatrics, highlighted the severity of the issue, pointing to 2,000+ reported child deaths in 2024 from just Kolkata, Bengaluru, and Mumbai, describing it as merely “the tip of the iceberg.”
Medical experts emphasized at a recent roundtable that almost every child contracts RSV by age two. The virus begins with cold-like symptoms but can rapidly develop into a severe lung infection requiring hospitalization within just three days. While many children recover without complications, doctors noted there’s no reliable way to predict which infants might develop serious conditions such as pneumonia or bronchiolitis.
Strategic Significance in Dr. Reddy’s Growth Portfolio
The Beyfortus® launch represents a key milestone in Dr. Reddy’s dual-track growth strategy, which focuses on both strengthening core businesses and building new value pools through strategic partnerships. According to the company’s FY2025 Integrated Annual Report, vaccines have been a significant driver of Dr. Reddy’s India business growth, which outpaced the Indian Pharmaceutical Market (IPM) at 8.4% versus 8.0% market growth.
Expanding Strategic Partnership Ecosystem
The Beyfortus® distribution agreement builds upon Dr. Reddy’s successful vaccine partnership with Sanofi established in 2024 as part of its strategy of “expanding innovation and building for tomorrow.”
This is part of a broader strategy of high-value collaborations to bring innovation to India that the company has been pursuing, including:
- A venture with Nestlé India to bring science-backed nutraceuticals to consumers
- Collaboration with Gilead Sciences to bring HIV drug Lenacapavir to low and lower-middle-income nations
- A licensing agreement with Takeda to introduce Vonoprazan, a novel acid blocker for treating gastric disorders in India
- Launch of Toripalimab (Zytorvi), the first immuno-oncology drug approved for nasopharyngeal carcinoma treatment in India
- Partnership with Bayer for marketing Vericiguat™, expanding Dr. Reddy’s cardiovascular medicine portfolio
Enhancing Prevention for a Critical Health Need
As highlighted in the medical roundtable discussions, RSV represents a significant health threat to infants in India, with routine testing and awareness around RSV remaining low despite the scale of the problem. The introduction of Beyfortus® addresses this critical gap in infant healthcare by providing a novel preventive option that can significantly reduce hospitalizations and complications.
With Beyfortus® already approved for use in the European Union, the U.S., China, Japan, and many other countries around the world, its introduction in India represents an important step in aligning the country’s preventive healthcare measures with global standards.
The launch positions Dr. Reddy’s to capitalize on growing awareness of RSV’s impact and increasing demand for preventive treatments in pediatric care. This launch aligns perfectly with the company’s stated philosophy of “Good Health Can’t Wait” and its commitment to addressing unmet patient needs by making expensive medicines affordable and accessible as well as improving disease management.
Read more from The Finance Herald
- China’s April Export Surge Shows the Trade Engine Still Has Buyers, Even as Costs Rise
- Americold’s EQT Venture Shows Cold Storage Is Being Valued Like Infrastructure
- Treasury’s Steady Auction Sizes Show How Washington Is Buying Time on a Bigger Deficit Problem
- Bullish’s $4.2 Billion Equiniti Deal Is a Bet That Tokenization Needs Real Market Plumbing
- Amex GBT’s $6.3 Billion Take-Private Deal Puts a New Price on Corporate Travel Platforms
Subscribe for More Articles Like This
Website Terms and Content Disclaimers
By using The Finance Herald, thefinanceherald.com, any subdomains thereof, and any affiliated or partner websites operated under the Wall Street Wire Network (collectively referred to as “Services”), you acknowledge that any and all Services provided are for informational and entertainment purposes only and do not constitute a recommendation for any particular stock, company, investment, commodity, security, transaction, or any other method of trading featured anywhere on The Finance Herald or affiliated platforms. The Finance Herald does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not specifically endorsed by The Finance Herald or the Wall Street Wire Network, and neither entity accepts responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered.
The Finance Herald, its employees, partners, affiliates, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible in any capacity to you or to any third party for any errors, inaccuracies, or omissions from the Services, including but not limited to market quotes, rumors, unverified chatter, financial data, and news reports; for any interruptions, delays, or transmission errors affecting the availability or accuracy of the Services; or for any damages or losses arising from or related to the use of, reliance on, or inability to access the Services. Some content published by The Finance Herald may reference market rumors, speculative chatter, or unconfirmed reports. Readers should be aware that while such unofficial information may be associated with market volatility, price movements based on speculative or incomplete data are subject to change rapidly upon further clarification or the release of official news or filings.
The Finance Herald reserves the right at any time to modify any part of its Terms of Service or any portion of the Services, including but not limited to the removal or addition of content, features, contributors, or affiliated content providers, or the introduction of any associated fees or usage conditions. Such changes will take effect immediately upon their publication across the Services and will apply to all users from the time of posting. Please note that trading in foreign currencies, stocks, options, and other securities involves substantial risk and may result in significant financial losses. Neither The Finance Herald nor its staff recommends that you buy, sell, or hold any security, and no part of the Services constitutes personalized investment advice. All information provided through the Services is general commentary intended for informational and entertainment use only. The Finance Herald disclaims any liability for loss or damage, including without limitation any loss of capital, profit, or opportunity, that may arise directly or indirectly from use of or reliance on the information contained within the Services. We encourage all users to conduct their own due diligence and consult with a certified financial advisor or licensed professional before making any financial decisions.
Content produced by or for The Finance Herald may not be reproduced, republished in full, or redistributed in any form without prior written permission from The Finance Herald or the Wall Street Wire Network, as applicable. Partner Content Disclosure: This content includes paid partnership content brought to you by Wall Street Wire. Wall Street Wire has received compensation from Dr. Reddy’s Laboratories for distribution and media promotion provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures